Drug agency Granules India on Monday stated the US well being regulator has issued two observations after the inspection of the Chantilly facility of its US-based subsidiary. “The USA Meals and Drug Administration (USFDA) has accomplished inspection of the ability of Granules Prescription drugs, an entirely owned international subsidiary of the corporate situated in Chantilly, Virginia, USA on June 25, 2021, with two minor observations,” stated in an announcement.
It is a pre-approval inspection for the merchandise filed from this facility, it added.
“We might be responding to the 2 observations inside the stipulated time interval,” Granules Prescription drugs Govt Director Priyanka Chigurupati stated.
Shares of Granules India had been buying and selling at Rs 317.30 per scrip on BSE, up 1.07 per cent from their earlier shut.